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Heavy smokers with respiratory symptom.
Videoendoscopy-based AFB
The system used was color CCD videoendoscopy based AF system. 
It has two light sources available; one is a Xenon lamp for white light 
image and the other is a diode laser which works as AFB mode excita-
tion light source. Infra-red light is eliminated by an Infra Red cut ﬁlter 
and white light is collected by the lens and transmitted to the objects 
through the light guide of the videoendoscope. In AFB mode, the ex-
citation light is on and is reﬂected by a beam splitter and collected and 
transmitted by the light guide. Excitation light is shone on the objects 
from the tip of the scope. The objective lens functions to eliminate the 
wavelength of excitation light and captures only AFB from the object 
(10). 
Results
A total of 257 high risk patients for lung cancer received AFB and 306 
biospy specimens from suspected areas were evaluated by experienced 
pathologists. Invasive cancers were equally diagnosed by both video-
endoscopy and AFB. AFB could diagnose all of 33 CIS lesions, while 
4 lesions could not be detected by white light. AFB diagnosed 60 of 67 
(90%) dysplastic lesions, while white light diagnosed 41 of 67 (61%). 
Discussion
Most studies in the past reported increased sensitivity of dysplasia or 
cancer in patients at high risk by autoﬂuorescence bronchoscopy com-
pared to white light alone (2-10).
However, morphological classiﬁcation of grades of dysplasias in 
objective way as well as the follow up protocol of high grade dysplasia 
should be discussed (11). Genetic anaysis and quantitative pathology 
may bring a clue of this problem. Also, optical biopsy of (endoscopic 
histological diagnosis without obtaining tissue sample) of dysplasia 
would be possible using optical coherence tomography in near future.
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Computed tomography (CT) scanning for various reasons be it abdo-
men symptoms, assessment of the coronary arteries or in screening 
for lung cancer will identify a large percentage of patients with one or 
more lung nodules. What constitutes a ditzel on CT? Neither Miriam-
Webster’s nor Stedman’s dictionaries deﬁne ditzel, but colloquial use 
suggests that it is an object of small stature that is of little consequence. 
The size of a ditzel not deﬁned, but for the sake of this discussion I 
will use a somewhat arbitrary distinction of a nodule of ≤ 5 mm that is 
non-calciﬁed. A nodule of this size has a low-but not no-likelihood of 
being a cancer. Nodules of this size are essentially not seen on chest 
radiographs unless they are calciﬁed. Larger sized nodules will not be 
addressed in this discussion. 
The results of prospective single-arm, observational studies in various 
countries show that rates of nodule detection at baseline screening 
ranges from 20-50% in participants at high risk for lung cancer. 1-6 The 
frequency of nodule detection has been demonstrated to be a function 
of CT slice thickness (collimation). Studies using 10 mm collimation 
have reported one or more nodules detected in about 25% of the partici-
pants. 1-3 Studies using 5 mm collimation ﬁnd one or more nodules 
in about 50% of the participants. 4-6 In a Vancouver study the nodules 
detection rate was 36% at 7mm collimation and increased to 60% when 
1.25 mm collimation was used. 6 In contrast, the rate of non-calciﬁed 
nodule detection at annual repeat scanning is less, in the range of 3-
18%. 2,3,7-9 Needless to say, CT screening frequently requires decisions 
regarding nodule management. At present, the optimal nodule manage-
ment of nodules of various sizes and character is in evolution. 
As cancer growth is a time-based principle, earlier implies smaller. 
The desire to detect small cancers is made problematic by the poten-
tial number of small benign lesions from which the malignant ones 
require identiﬁcation. Herein lies the crux of the problem presented to 
the clinician or researcher evaluating the patient or participant who has 
had a CT and one or more nodules are found. Optimal evaluation of 
screen-detected lesions identiﬁes cancer with haste and avoids resection 
of benign lesions. If the evolving technologic advance of CT leads to 
smaller and smaller malignancies, this may be of beneﬁt to the patient-
as a consequence, it would appear that the detection of more nodules 
and therefore an increasing number of false-positives may well be the 
good news rather than the bad news. 
The concern over high false-positive rates has led some authors to 
change the deﬁnition of a positive scan by considering noncalciﬁed 
nodules that are less that 5 mm as negative. This does serve to reduce 
the number of false-positive scans, but unfortunately, some of these 
small nodules are malignant and also one increases the rate of false-
negative scans. In the ELCAP study, 1% of the nodules detected at 2-5 
mm were malignant. 1 In the Mayo study, Swensen reported that 5 of 
40 lung cancers identiﬁed were less than 5 mm in diameter at initial 
detection. 9 McWilliams reported that 18% of the cancers identiﬁed by 
CT screening were detected when less than 4 mm. 10 The ideal screen-
ing study would have a zero false-negative rate. If we, by convention, 
determine that nodules of a few millimeters in size are to be considered 
negative, we enhance the likelihood of false-negative scans. This is 
borne out in an Italian study in which non-calciﬁed nodules of 5 mm 
or less in maximal diameter considered as negative. 3 Annual repeat 
scanning identiﬁed 11 cancers, and 6 of these were classiﬁed as benign 
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at baseline scanning because of their small size or inﬂammatory charac-
ter. Similarly in the IELCAP report, False-positives will occur with CT 
screening and false-positive rates may be high, but lowering these rates 
at the consequence of increasing the false-negative studies is seems 
undesirable. 
The workup of screen-detected nodules needs to take into account 
the high prevalence of benign nodules. Perhaps it is semantics, but 
considering the very small nodule as a “micronodule” by the NLST 
study appears the more appropriate way to handle the high likelihood 
of benignancy in the ditzel detected rather than to consider them as 
negative. Perhaps CT follow-up at one year is all that is needed for the 
vast majority of nodules detected at CT screening, but this should still 
be considered in the context of follow-up rather than considering the 
initial scan as negative and starting anew at 12 months as though the 
nodule never existed. 
There are a number of nodule characteristics that can indicate that a 
nodule is more likely malignant and these include nodule size, lack of 
calciﬁcation, spiculated margins and nodule growth. For the sake of the 
non-calciﬁed ditzel, nodule growth remains the most helpful feature 
in follow-up as these nodules are too small to reliably discern surface 
characteristics. Whether or not a nodule is a baseline nodule versus a 
new nodule, repeat scanning may affect its likelihood of malignancy. 
Studies to date vary somewhat in this regard, though most show a 
signiﬁcant increase in the likelihood of malignancy if a nodule is new 
at annual scanning compared to a nodule present at baseline. In the 
ELCAP study, there were 233 baseline nodules in 1,000 participants. 
Twenty-seven nodules or 11.5% were proven malignant. On repeat 
annual scanning, there were 63 new nodules identiﬁed, and 23 of these 
were identiﬁed on baseline scanning in retrospect. Of the nodules 
remaining, 7 were proven malignant or 17.5% of the new nodules. 8 In 
the Mayo Clinic study, there were more than 1646 nodules present at 
baseline with 33 subsequently proven malignant for a rate of 1.9%.9 At 
repeat annual scans, there were 1710 new nodules identiﬁed and 34 of 
these were proven malignant for a rate of 2.0% or a similar rate of ma-
lignancy among the baseline nodules. Favoring a higher rate of malig-
nancy among new nodules detected was the study by Pastorini. There 
were 284 nodules identiﬁed at baseline of which 11 were malignant 
(3.9%). On ﬁrst annual scan, there were 127 new noncalciﬁed nodules, 
and 11 of these were malignant for a rate of 8.6%. The differences in 
screening methodology as well as threshold for calling a scan abnormal 
make comparison between these studies difﬁcult. However, the internal 
comparison of four of the studies supports that our index of suspicion 
for a new nodule detected at annual scan should be somewhat higher 
for malignancy compared to one detected at baseline. 
The vast majority of nodules detected by CT screening are too small 
for further evaluation with contrast enhancement, PET scanning, or 
needle biopsy - this is certainly true for the ditzel as we have deﬁned 
it for this discussion. Clearly, the most appropriate intervention for 
most screen-detected noncalciﬁed nodules < 5 mm is no intervention at 
all. As difﬁcult as it often is for physicians to do nothing but observe, 
follow-up CT is the mainstay of evaluation for the nodules of this size. 
The interval of follow-up is somewhat controversial. In a survey of 
radiologists asked to recommend management of clinical scenarios of 
“ditzels” 3-5 mm in size, short term follow-up (3-6 months) was the 
most frequent recommendation. 11 For current or former smokers, the 
Fleischner Society has recommended 1 year follow-up for nodules ≤ 
5mm and, if unchanged at that interval, no further follow-up; for the 5 
mm nodule the recommendation is CT in 6-12 months and again at 18-
24 months if unchanged. 12 
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Despite the advances in surgical treatment and multimodality treatment, 
lung cancer is still the leading cause of death from malignant disease 
worldwide. Accurate staging of the disease is important not only to 
determine the prognosis but also to decide the most suitable treatment 
plan. During the staging process, mediastinal lymph node staging 
is one of the most important factors that affect the patient outcome. 
Non-invasive staging which mainly consists of conventional imaging 
methods available for the assessment of the mediastinum includes chest 
CT, positron emission tomography (PET) transesophageal ultrasonog-
raphy (EUS) and endobronchial ultrasound (EBUS) using the radial 
probe. Imaging alone is inaccurate and therefore tissue sampling is 
the preferred and most reliable. On the other hand, invasive staging 
offers tissue proof of the mediastinum. Mediastinoscopy is still the 
gold standard for mediastinal lymph node staging. However, it requires 
general anesthesia and the complications cannot be ignored. Other 
invasive staging modalities of the mediastinum include conventional 
bronchoscopic transbronchial needle aspiration (TBNA), EUS-guided 
ﬁne needle aspiration (EUS-FNA), CT ﬂuoroscopy guided TBNA, and 
EBUS-guided TBNA using the radial probe. However, each of these 
methods has its limitations.
There has been a need for a new modality with a high yield which en-
ables pulmonologists and thoracic surgeons to assess the mediastinum 
easily and safely. In 2002, we started to develop a new convex probe 
